HC Wainwright Reiterates Neutral Rating for Avalo Therapeutics (NASDAQ:AVTX)

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “neutral” rating reissued by investment analysts at HC Wainwright in a report issued on Thursday,Benzinga reports.

A number of other research analysts have also recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $18.00 target price on shares of Avalo Therapeutics in a research note on Thursday. BTIG Research initiated coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Piper Sandler initiated coverage on Avalo Therapeutics in a research note on Friday, February 28th. They set an “overweight” rating and a $48.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Avalo Therapeutics has an average rating of “Moderate Buy” and an average target price of $35.33.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX opened at $7.66 on Thursday. The business’s 50 day moving average is $7.45 and its two-hundred day moving average is $9.11. Avalo Therapeutics has a 1-year low of $4.60 and a 1-year high of $34.46.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AVTX. Ikarian Capital LLC lifted its holdings in Avalo Therapeutics by 1,673.0% during the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after buying an additional 915,629 shares during the period. RA Capital Management L.P. purchased a new stake in Avalo Therapeutics during the third quarter worth $9,186,000. Geode Capital Management LLC lifted its holdings in Avalo Therapeutics by 937.0% during the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after buying an additional 94,742 shares during the period. Bank of Montreal Can purchased a new stake in Avalo Therapeutics during the fourth quarter worth $446,000. Finally, Walleye Capital LLC purchased a new stake in Avalo Therapeutics during the fourth quarter worth $145,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.